Proteon Therapeutics grabs $15.2M financing

Waltham, MA-based Proteon Therapeutics has raised $15.2 million in financing, the Boston Business Journal reports, citing SEC documents. The new funding is in exchange for equity and options and follows the company's initiation of a mid-stage trial of its lead drug, PRT-201, which the firm says aims to "improve the outcomes associated with the surgical creation of vascular accesses in chronic kidney disease patients undergoing hemodialysis." Novartis ($NVS) has an option to acquire Proteon after the small firm completes Phase II development of the drug. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."